Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.

SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $78.6 million in its fourth quarter. On a per-share basis, the San Carlos ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Friday, Piper Sandler analyst Joseph Catanzaro adjusted the price target for Iovance Biotherapeutics (NASDAQ:IOVA) to $6.00, down from the previous $7.50. The ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...

IOVA opened at $5.78 on Friday. The company’s 50 day simple moving average is $6.44 and its 200 day simple moving average is $8.71. Iovance Biotherapeutics has a 1 year low of $5.05 and a 1 year ...